Wamberg Genomic Advisors Announces The Penn Mutual Life Insurance Company to Provide Cancer Guardian as a Benefit to its Associates

By a News Reporter-Staff News Editor at Cancer Weekly -- Wamberg Genomic Advisors announced that The Penn Mutual Life Insurance Company (Penn Mutual) will be providing the Cancer Guardian™ program to its associates, plus their spouses and dependents starting on October 1st. Since 1847, Penn Mutual has been committed to helping people live life with confidence. At the heart of this purpose is the belief that life insurance is central to a sound financial plan. Their network of trusted advisers is dedicated to helping individuals, families and businesses achieve their dreams. Penn Mutual engaged Pentra, LLC, An Alera Group company to assist in the evaluation of the Cancer Guardian program (see also Wamberg Genomic Advisors).

Cancer Guardian is a program that provides guidance, resources and access to leading-edge DNA testing at the time of a cancer diagnosis. Wamberg recently announced enhancements to Cancer Guardian to now include expanded Comprehensive Cancer Support.

Keywords for this news article include: Cancer, Genetics, Oncology, Health and Medicine, Insurance Companies, Wamberg Genomic Advisors.